PetMed Express (PETS) Expected to Announce Earnings on Wednesday

PetMed Express (NASDAQ:PETS) is projected to release its Q2 2026 results before the market opens on Wednesday, December 24th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, December 23, 2025 at 12:00 AM ET.

PetMed Express (NASDAQ:PETS) last posted its quarterly earnings results on Tuesday, October 14th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.60). The business had revenue of $46.47 million during the quarter. PetMed Express had a negative net margin of 2.76% and a negative return on equity of 6.76%. On average, analysts expect PetMed Express to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

PetMed Express Stock Performance

NASDAQ:PETS opened at $3.65 on Friday. The stock has a fifty day moving average price of $2.34 and a two-hundred day moving average price of $2.89. The stock has a market capitalization of $78.00 million, a price-to-earnings ratio of -12.17 and a beta of 0.75. PetMed Express has a 1 year low of $1.57 and a 1 year high of $5.58.

Analyst Upgrades and Downgrades

PETS has been the subject of a number of research analyst reports. Zacks Research upgraded shares of PetMed Express from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Wall Street Zen lowered shares of PetMed Express from a “hold” rating to a “sell” rating in a research report on Saturday, October 18th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of PetMed Express in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Sell” and a consensus price target of $3.20.

Institutional Trading of PetMed Express

A number of large investors have recently made changes to their positions in PETS. Goldman Sachs Group Inc. lifted its holdings in PetMed Express by 59.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 33,209 shares of the company’s stock valued at $139,000 after purchasing an additional 12,360 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in PetMed Express in the 2nd quarter valued at $51,000. Bridgeway Capital Management LLC lifted its stake in shares of PetMed Express by 96.2% during the 2nd quarter. Bridgeway Capital Management LLC now owns 40,800 shares of the company’s stock worth $135,000 after purchasing an additional 20,000 shares during the period. Oxford Asset Management LLP purchased a new position in shares of PetMed Express during the 2nd quarter worth $55,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of PetMed Express by 5.4% during the third quarter. Dimensional Fund Advisors LP now owns 481,517 shares of the company’s stock worth $1,209,000 after purchasing an additional 24,624 shares during the last quarter. Institutional investors and hedge funds own 73.33% of the company’s stock.

About PetMed Express

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.